[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ZA200506790B - Arylvinylazacycloalkane compounds and method of preparation and use thereof - Google Patents

Arylvinylazacycloalkane compounds and method of preparation and use thereof

Info

Publication number
ZA200506790B
ZA200506790B ZA200506790A ZA200506790A ZA200506790B ZA 200506790 B ZA200506790 B ZA 200506790B ZA 200506790 A ZA200506790 A ZA 200506790A ZA 200506790 A ZA200506790 A ZA 200506790A ZA 200506790 B ZA200506790 B ZA 200506790B
Authority
ZA
South Africa
Prior art keywords
preparation
arylvinylazacycloalkane
compounds
arylvinylazacycloalkane compounds
Prior art date
Application number
ZA200506790A
Other languages
English (en)
Inventor
Jeffrey D Schmitt
Arielle Genevois-Borella
Michael Cheve
Gary M Dull
Marc Capet
Original Assignee
Targacet Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targacet Inc filed Critical Targacet Inc
Publication of ZA200506790B publication Critical patent/ZA200506790B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA200506790A 2003-03-05 2005-08-24 Arylvinylazacycloalkane compounds and method of preparation and use thereof ZA200506790B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/379,868 US7098331B2 (en) 2003-03-05 2003-03-05 Arylvinylazacycloalkane compounds and methods of preparation and use thereof

Publications (1)

Publication Number Publication Date
ZA200506790B true ZA200506790B (en) 2006-05-31

Family

ID=32926772

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200506790A ZA200506790B (en) 2003-03-05 2005-08-24 Arylvinylazacycloalkane compounds and method of preparation and use thereof

Country Status (32)

Country Link
US (8) US7098331B2 (pl)
EP (3) EP2085395B1 (pl)
JP (3) JP4663627B2 (pl)
KR (4) KR100953150B1 (pl)
CN (3) CN100526308C (pl)
AR (3) AR043469A1 (pl)
AT (3) ATE517893T1 (pl)
AU (3) AU2004217903B2 (pl)
BR (1) BRPI0409576A (pl)
CA (1) CA2516514C (pl)
CL (1) CL2004000452A1 (pl)
CY (2) CY1110391T1 (pl)
DE (2) DE602004031165D1 (pl)
DK (2) DK1601670T3 (pl)
EA (3) EA019240B1 (pl)
ES (3) ES2309507T3 (pl)
GT (1) GT200400033A (pl)
HK (3) HK1084949A1 (pl)
IL (3) IL170155A (pl)
JO (1) JO2488B1 (pl)
MX (1) MXPA05009386A (pl)
NO (3) NO331920B1 (pl)
NZ (1) NZ541795A (pl)
PA (1) PA8597201A1 (pl)
PE (1) PE20040930A1 (pl)
PL (5) PL1601670T3 (pl)
PT (2) PT1601670E (pl)
SI (2) SI1601670T1 (pl)
TW (3) TWI339662B (pl)
UY (1) UY28218A1 (pl)
WO (1) WO2004078752A1 (pl)
ZA (1) ZA200506790B (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7098331B2 (en) * 2003-03-05 2006-08-29 Targacept, Inc. Arylvinylazacycloalkane compounds and methods of preparation and use thereof
FR2896800B1 (fr) * 2006-01-30 2008-04-11 Servier Lab Nouveaux composes pyridinylaminoalkylene-et pyridinyloxyalkylene-cyclopropanamines polysubstitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
WO2008157365A2 (en) * 2007-06-15 2008-12-24 Targacept, Inc. Vinylazacycloalkanes for treating neuropathic pain
EP2296640A1 (en) * 2008-05-12 2011-03-23 Targacept Inc. Methods for preventing the development of retinopathy by the oral administration of nnr ligands
US9145396B2 (en) 2008-12-01 2015-09-29 Targacept, Inc. Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine
TW201024283A (en) * 2008-12-01 2010-07-01 Targacept Inc Synthesis and novel salt forms of (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine
RU2533819C2 (ru) * 2008-12-01 2014-11-20 Таргасепт, Инк. Синтез и новые солевые формы (r)-5-((e)-2-(пирролидин-3-илвинил)пиримидина
WO2010080757A2 (en) 2009-01-07 2010-07-15 Astrazeneca Ab Combinations with an alpha-4beta-2 nicotinic agonist
US20120157477A1 (en) * 2009-06-17 2012-06-21 Targacept, Inc. Reversal of l-dopa-induced dyskinesia by neuronal nicotinic receptor ligands
AU2010328419A1 (en) 2009-12-07 2012-06-21 Targacept, Inc. 3,6-diazabicyclo[3.1.1]heptanes as neuronal nicotinic acetylcholine receptor ligands
CA2792157A1 (en) * 2010-03-11 2011-09-15 Targacept, Inc. Arylvinylazacycloalkane compounds for constipation
US20110274628A1 (en) * 2010-05-07 2011-11-10 Borschke August J Nicotine-containing pharmaceutical compositions
US20140081714A1 (en) * 2012-09-19 2014-03-20 Salesforce.Com, Inc. Systems and methods of rewarding users in an on-demand system
US20140278929A1 (en) * 2013-03-15 2014-09-18 Yahoo! Inc. System and method identifying opportunities for advertising entities based on user goal achievement
MX2018012230A (es) 2016-04-07 2019-03-28 Oyster Point Pharma Inc Métodos para tratar enfermedades oculares.
KR101848601B1 (ko) * 2016-07-27 2018-04-12 송기봉 일회용 위생 티슈
EP3820443A1 (en) 2018-07-10 2021-05-19 Oyster Point Pharma, Inc. Combinations of positive allosteric modulators and nicotinic acetylcholine receptor agonists for treating ocular conditions
WO2020014217A1 (en) 2018-07-10 2020-01-16 Oyster Point Pharma, Inc. Methods of treating ocular conditions
WO2021222230A1 (en) 2020-04-28 2021-11-04 Oyster Point Pharma, Inc. Local administration of nicotinic acetylcholine receptor agonists for the inhibition of coronavirus infections

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989000158A1 (en) 1987-07-02 1989-01-12 Pfizer Inc. Bridged-diazabicycloalkyl quinolone carboxylic acids and esters
US4922901A (en) * 1988-09-08 1990-05-08 R. J. Reynolds Tobacco Company Drug delivery articles utilizing electrical energy
US5187166A (en) * 1990-07-31 1993-02-16 Nisshin Flour Milling Co., Ltd. Azabicyclo derivatives and their use as antiemetics
IL107184A (en) 1992-10-09 1997-08-14 Abbott Lab Heterocyclic ether compounds that enhance cognitive function
US5852041A (en) * 1993-04-07 1998-12-22 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acethylcholine receptors
IT1274018B (it) * 1994-02-23 1997-07-14 Riace Ets Derivati del 3,8-diazabiciclo(3.2.1.)ottano ad attivita' analgesica
GB2295387A (en) 1994-11-23 1996-05-29 Glaxo Inc Quinazoline antagonists of alpha 1c adrenergic receptors
US5597919A (en) * 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5604231A (en) * 1995-01-06 1997-02-18 Smith; Carr J. Pharmaceutical compositions for prevention and treatment of ulcerative colitis
US5585388A (en) 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
US5583140A (en) * 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders
IL118279A (en) 1995-06-07 2006-10-05 Abbott Lab Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission
US5616716A (en) * 1996-01-06 1997-04-01 Dull; Gary M. (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
AT403803B (de) 1996-04-19 1998-05-25 Sanochemia Ltd Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
US5663356A (en) * 1996-04-23 1997-09-02 Ruecroft; Graham Method for preparation of aryl substituted alefinic secondary amino compounds
US6437138B1 (en) * 1996-06-06 2002-08-20 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
US5629325A (en) 1996-06-06 1997-05-13 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
EP1027336B1 (en) 1997-10-27 2004-10-06 Neurosearch A/S Heteroaryl diazacycloalkanes as cholinergic ligands at nicotinic acetylcholine receptors
WO2000075110A1 (en) 1999-06-07 2000-12-14 Targacept, Inc. Pharmaceutical compositions and methods for use
EP1212319A2 (en) 1999-09-14 2002-06-12 Abbott Laboratories 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission
CA2389645A1 (en) 1999-11-01 2001-05-10 Targacept, Inc. Aryl olefinic azacyclic, and aryl acetylenic azacyclic compounds, pharmaceutical compositions containing them and their use as inhibitors of nicotinic cholinergic receptors
US6624167B1 (en) * 2000-08-04 2003-09-23 Targacept, Inc. Pharmaceutical compositions and methods for use
US6881738B2 (en) 2001-07-19 2005-04-19 Medical College Of Georgia Research Institute Analogs of choline for neuroprotection and cognitive enhancement in neurodegenerative disorders
US7098331B2 (en) * 2003-03-05 2006-08-29 Targacept, Inc. Arylvinylazacycloalkane compounds and methods of preparation and use thereof

Also Published As

Publication number Publication date
US8633222B2 (en) 2014-01-21
CN101255155A (zh) 2008-09-03
AR070570A2 (es) 2010-04-21
US7098331B2 (en) 2006-08-29
US20040176348A1 (en) 2004-09-09
NO332293B1 (no) 2012-08-20
KR20090021227A (ko) 2009-02-27
EA200501425A1 (ru) 2006-02-24
PL215059B1 (pl) 2013-10-31
NO20092231L (no) 2005-10-03
TW200927745A (en) 2009-07-01
ES2389106T3 (es) 2012-10-23
CN100526308C (zh) 2009-08-12
US7714001B2 (en) 2010-05-11
EP1601670B1 (en) 2008-05-07
CN101550132A (zh) 2009-10-07
PL378415A1 (pl) 2006-04-03
US20100267776A1 (en) 2010-10-21
HK1116800A1 (en) 2009-01-02
IL197890A (en) 2013-11-28
EP1947100A1 (en) 2008-07-23
KR101185541B1 (ko) 2012-09-24
EA014714B1 (ru) 2011-02-28
KR20060006006A (ko) 2006-01-18
JP5537084B2 (ja) 2014-07-02
CA2516514A1 (en) 2004-09-16
PT2085395E (pt) 2011-04-20
TW200505909A (en) 2005-02-16
US20150164894A1 (en) 2015-06-18
ATE394394T1 (de) 2008-05-15
JP2009292825A (ja) 2009-12-17
CN101550132B (zh) 2012-03-28
NO20091888L (no) 2005-10-03
AU2008258188B2 (en) 2011-02-24
KR101018083B1 (ko) 2011-03-02
PL394604A1 (pl) 2011-07-18
CL2004000452A1 (es) 2005-05-20
AU2008258188A1 (en) 2009-01-15
TWI377204B (en) 2012-11-21
HK1084949A1 (en) 2006-08-11
ES2385941T3 (es) 2012-08-03
JO2488B1 (en) 2009-10-05
EA200801764A1 (ru) 2008-12-30
KR20120014236A (ko) 2012-02-16
EA010870B1 (ru) 2008-12-30
ATE496046T1 (de) 2011-02-15
US8067443B2 (en) 2011-11-29
NO331920B1 (no) 2012-04-30
PL2085395T3 (pl) 2011-05-31
AU2004217903B2 (en) 2010-03-04
CA2516514C (en) 2012-02-07
NO20054120L (no) 2005-10-03
DE602004013553D1 (de) 2008-06-19
IL197889A (en) 2013-03-24
EA019240B1 (ru) 2014-02-28
EA200900706A1 (ru) 2009-10-30
SI1601670T1 (sl) 2008-10-31
TW200927746A (en) 2009-07-01
US20110152293A1 (en) 2011-06-23
PL216979B1 (pl) 2014-06-30
US20100010042A1 (en) 2010-01-14
AR070569A2 (es) 2010-04-21
CY1110391T1 (el) 2015-04-29
SI2085395T1 (sl) 2011-05-31
PL394600A1 (pl) 2011-07-18
CY1111615T1 (el) 2015-10-07
JP2010001296A (ja) 2010-01-07
US8063068B2 (en) 2011-11-22
TWI339662B (en) 2011-04-01
EP1947100B1 (en) 2011-07-27
AU2008258187B2 (en) 2010-08-05
GT200400033A (es) 2005-05-29
CN1756754A (zh) 2006-04-05
AU2008258187A1 (en) 2009-01-15
PL1601670T3 (pl) 2008-10-31
UY28218A1 (es) 2005-06-30
DK1601670T3 (da) 2008-08-25
IL170155A (en) 2013-08-29
JP4663627B2 (ja) 2011-04-06
KR20090021228A (ko) 2009-02-27
ATE517893T1 (de) 2011-08-15
NZ541795A (en) 2008-03-28
DK2085395T3 (da) 2011-04-18
KR100953150B1 (ko) 2010-04-19
PA8597201A1 (es) 2004-09-28
JP5537085B2 (ja) 2014-07-02
DE602004031165D1 (de) 2011-03-03
EP2085395A1 (en) 2009-08-05
MXPA05009386A (es) 2005-11-04
EP1601670A1 (en) 2005-12-07
AU2004217903A1 (en) 2004-09-16
US20060094732A1 (en) 2006-05-04
US20080293778A1 (en) 2008-11-27
AR043469A1 (es) 2005-07-27
ES2309507T3 (es) 2008-12-16
PE20040930A1 (es) 2005-02-18
BRPI0409576A (pt) 2006-04-18
US20140107164A1 (en) 2014-04-17
EP2085395B1 (en) 2011-01-19
NO20054120D0 (no) 2005-09-05
HK1130254A1 (en) 2009-12-24
PT1601670E (pt) 2008-07-11
JP2006519868A (ja) 2006-08-31
WO2004078752A1 (en) 2004-09-16

Similar Documents

Publication Publication Date Title
HK1116800A1 (en) Arylvinylazacycloalkane compounds and methods of preparation and use thereof
AU2003217870A8 (en) Pini-modulating compounds and methods of use thereof
AU2003213673A8 (en) Pin1-modulating compounds and methods of use thereof
GB0325192D0 (en) Method of use
TWI367766B (en) Immunoglobulin formulation and method of preparation thereof
IL176958A0 (en) Compounds and methods of use
AU2003225669A1 (en) Pin1-modulating compounds and methods of use thereof
AU2003225668A1 (en) Pin1-modulating compounds and methods of use thereof
EP1639086A4 (en) RNA INTERFERASES AND METHODS OF USE
IL169648A0 (en) Novel structures and method of preparation
EP1567515A4 (en) NEW LAPACHONE COMPOUNDS AND METHODS FOR THE APPLICATION
EP1625111A4 (en) THYRONAMINE DERIVATIVES AND ANALOGUES AND METHODS OF USE THEREOF
EP1476150A4 (en) CARBOXY FULLERES AND USE METHOD THEREFOR
IL175657A0 (en) Derivatives of dihydronepetalactone and method for preparation
EP1663255A4 (en) WITHANAMID AND WITHANOLID COMPOSITIONS AND APPLICATION METHOD THEREFOR
EP1678157A4 (en) Heterocyclic compounds and process for their preparation and use
EP1633749A4 (en) DEAZAFLAVIN COMPOUNDS AND METHODS OF USE
EP1625141A4 (en) GRP94-BASED COMPOSITIONS AND METHODS OF USE THEREOF
EP1812451A4 (en) COMPOUNDS AND METHODS OF USE THEREOF
EP1545287A4 (en) VASOREGULATORY COMPOUNDS AND METHODS RELATING TO THEIR USE
AU2003282593A8 (en) Polyphenolamine composition and method of use
GB0304555D0 (en) Compounds and methods of manufacture
EP1686990A4 (en) 2-GUANIDINYLIMIDAZOLIDINEDIONE COMPOUNDS: METHODS OF PREPARATION AND USE
AU2002333157A1 (en) Compound for treatment of anxiety and methods of preparation and use thereof
EP1591440A4 (en) ALANINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THEIR USE